Trial
NCT04781543
A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Diffuse Cutaneous Systemic Sclerosis
Intervention
HZN-825 BID
Why stopped
The study was terminated due to meeting pre-defined criteria for futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-20